PURPOSE: Multimeric arginine-glycine-aspartic acid (RGD) peptides have advantages for imaging integrin αvβ3 expression. Here, we compared the in vitro and in vivo behavior of three different Ga-68-labeled multimeric Fusarinine C-RGD (FSC-RGD) conjugates, whereby RGD was coupled directly, via a succinic acid or PEG linker (FSC(RGDfE)3, FSC(succ-RGD)3, FSC(Mal-RGD)3). The positron emission tomography/X-ray computed tomography (PET/CT) imaging properties were further compared using [(68)Ga]FSC(succ-RGD)3 with the monomeric [(68)Ga]NODAGA-RGD in a murine tumor model. PROCEDURE: FSC-RGD conjugates were labeled with Ga-68, and stability properties were studied. For in vitro characterization, the partition coefficient, integrin αvβ3 binding affinity, and cell uptake were determined. To characterize the in vivo properties, biodistribution studies and microPET/CT were carried out using mice bearing either human M21/M21-L melanoma or human U87MG glioblastoma tumor xenografts. RESULTS: All FSC-RGD conjugates were quantitatively labeled with Ga-68 within 10 min at RT. The [(68)Ga]FSC-RGD conjugates exhibited high stability and hydrophilic character, with only minor differences between the different conjugates. In vitro and in vivo studies showed enhanced integrin αvβ3 binding affinity, receptor-selective tumor uptake, and rapid renal excretion resulting in good imaging properties. CONCLUSIONS: The type of linker between FSC and RGD had no pronounced effect on targeting properties of [(68)Ga]FSC-RGD trimers. In particular, [(68)Ga]FSC(succ-RGD)3 exhibited improved properties compared to [(68)Ga]NODAGA-RGD, making it an alternative for imaging integrin αvβ3 expression.

Department of Nuclear Medicine Guangdong General Hospital and Guangdong Academy of Medical Sciences Guangzhou China

Department of Nuclear Medicine Medical University Innsbruck Innsbruck Austria

Department of Nuclear Medicine Radboud University Nijmegen Medical Centre Nijmegen The Netherlands

Division of Molecular Biology Medical University Innsbruck Innsbruck Austria

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Haubner R, Maschauer S, Prante O. PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed Res Int. 2014;2014:871609. PubMed PMC

Haubner R, Gratias R, Diefenbach B, et al. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J Am Chem Soc. 1996;118:7461–7472. doi: 10.1021/ja9603721. DOI

Marchi‐Artzner V, Lorz B, Hellerer U, et al. Selective adhesion of endothelial cells to artificial membranes with a synthetic RGD-lipopeptide. Chemistry. 2001;7:1095–1101. doi: 10.1002/1521-3765(20010302)7:5<1095::AID-CHEM1095>3.0.CO;2-B. PubMed DOI

Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumor targeting. Front Biosci. 2009;14:872–886. doi: 10.2741/3283. PubMed DOI

Gaertner FC, Kessler H, Wester HJ, et al. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S126–S138. doi: 10.1007/s00259-011-2028-1. PubMed DOI

Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin αvβ3 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472–487. doi: 10.1021/mp060049x. PubMed DOI

Haubner R, Wester H-J, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326–336. PubMed

Haubner R, Wester H-J, Weber WA, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–1785. PubMed

Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61–69. doi: 10.1021/bc034170n. PubMed DOI

Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F] Galacto-RGD. PLOS Med. 2005;2 doi: 10.1371/journal.pmed.0020070. PubMed DOI PMC

Knetsch PA, Petrik M, Griessinger CM, et al. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging. 2011;38:1303–1312. doi: 10.1007/s00259-011-1778-0. PubMed DOI

Pohle K, Notni J, Bussemer J, et al. 68Ga-NODAGA-RGD is a suitable substitute for 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39:777–784. doi: 10.1016/j.nucmedbio.2012.02.006. PubMed DOI

Notni J, Pohle K, Wester H-J. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of 68Ga-TRAP(RGD)3. Nucl Med Biol. 2013;40:33–41. doi: 10.1016/j.nucmedbio.2012.08.006. PubMed DOI

Knetsch PA, Zhai C, Rangger C, et al. [68Ga]FSC-(RGD)3, a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold—synthesis and evaluation. Nucl Med Biol. 2015;42:115–122. doi: 10.1016/j.nucmedbio.2014.10.001. PubMed DOI PMC

Zhai C, Summer D, Rangger C, et al. Fusarinine C, a novel siderophore-based bifunctional chelator for radiolabeling with Gallium-68. J Labelled Comp Radiopharm. 2015;58:209–214. doi: 10.1002/jlcr.3286. PubMed DOI PMC

Zhai C, Summer D, Rangger C, et al. Novel bifunctional cyclic chelator for 89Zr labeling–radiolabeling and targeting properties of RGD conjugates. Mol Pharm. 2015;12:2142–2150. doi: 10.1021/acs.molpharmaceut.5b00128. PubMed DOI PMC

Petrik M, Zhai C, Novy Z, et al. (2015) In vitro and in vivo comparison of selected Ga-68 and Zr-89 labelled siderophores. Mol Imaging Biol, doi:10.1007/s11307-11015-10897-11306. PubMed PMC

Haubner R, Wester HJ, Reuning U, et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061–1071. PubMed

Yardeni T, Eckhaus M, Morris HD, et al. Retro-orbital injections in mice. Lab animal. 2011;40:155. doi: 10.1038/laban0511-155. PubMed DOI PMC

Liu S. Radiolabeled cyclic RGD peptide bioconjugates as radiotracers targeting multiple integrins. Bioconjug Chem. 2015;26:1413–1438. doi: 10.1021/acs.bioconjchem.5b00327. PubMed DOI PMC

Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme

Siderophores for molecular imaging applications

Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding